TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
TORL BioTherapeutics has raised $96.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
TORL BioTherapeutics's investors include RA Capital Management, Goldman Sachs, Perceptive Advisors, Blue Owl, Vertex Ventures HC.
TORL BioTherapeutics is headquartered in Culver City, United States.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
TORL BioTherapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TORL BioTherapeutics — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/torl-biotherapeutics. Accessed August 12, 2026.
VCBacked. (2025). TORL BioTherapeutics — Funding & Investors. Retrieved August 12, 2026, from https://www.vcbacked.co/company/torl-biotherapeutics
{{cite web |title=TORL BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/torl-biotherapeutics |website=VCBacked |access-date=August 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated